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myocardial infarction (STEMI), the survivors may develop more
heart failure in the long term.
We contend that we currently find ourselves amidst a shift in dis-
ease manifestations of atherosclerosis due to altered demographics,
attendant changes in risk factor profiles, efforts to control tobacco
abuse, and the increased prevalence of statin treatment. Myocardial
infarction has ‘gone global’, not only affecting predominantly middle-
aged Caucasian males in higher socioeconomic strata, and no longer
associates mainly with cigarette smoking, hypertension, and high
low-density lipoprotein (LDL). Women, non-Caucasians, younger
individuals, and those with obesity, insulin resistance or frank dia-
betes, and high triglycerides and low high-density lipoprotein
(HDL) represent an increasing proportion of our patients with ACS.
We also now find ourselves the midst of a transition in the pres-
entation of ACS, with STEMI on the wane and non-ST segment
elevation myocardial infarction (NSTEMI) rising.11 While much of
the increase in NSTEMI might result from the introduction of
ever more sensitive troponin assays, shifting ACS previously classi-
fied as ‘unstable angina’ to NSTEMI, the decline in STEMI, and rise in
NSTEMI began before the use of such assays. The temporal decline
in STEMI incidence accompanies a substantial decline in stroke inci-
dence and case fatality.12,13 These findings strengthen our propos-
ition regarding a transition in the pathological mechanisms and
presentations of the acute complications of atherosclerotic disease.
Concomitant with this trend from STEMI dominance towards
NSTEMI, statin use has risen.14 While the temporal coincidence
of a shift in ACS pathogenesis and the penetration of statin therapy
do not prove causality, substantial evidence supports such a
relationship. Animal studies show that lipid-lowering and/or statin
treatment can reinforce the fibrous cap, decrease the lipid pool,
and reduce inflammation.15 Human imaging studies buttress the
notion that statin therapy reduces the lipid content of plaques and
augments the proportion of the plaque composed of fibrous tissue,
a characteristic associated with resistance to rupture.16,17 Studies on
retrieved atherosclerotic plaque specimens in the Athero-Express
collection have shown a time-dependent shift in the morphology
of human atherosclerotic plaques over the last dozen years or so.
Plaques obtained from more recent patients with symptomatic
carotid artery disease reveal significantly more fibrous, non-
inflammatory characteristics. This temporal trend towards plaques
with morphologic characteristics of ‘stability’ in biobanked plaques
also applied to asymptomatic patients. Surprisingly, statin use only
explains part of this shift towards more fibrous lesions. Thus, other
determinants merit careful consideration, including public policies
that reduce passive smoking. Analysis of the histologic features
of .1500 plaques showed that large atheromata with high macro-
phage content have significantly declined from 2002 to 2011, sup-
porting our contention that the classical notion of the ‘vulnerable
plaque’ has receded in relevance.18 Although obtaining plaque
Table 1 Challenges to the ‘vulnerable plaque’ concept
† Thin-capped, lipid-rich atheromata are not solitary, rather often
multiple, and affect several arterial beds in the same individual.
† Thin-capped, lipid-rich atheromata most often persist for years
without causing a clinical event.
† The risk profile and demographics of acute coronary syndrome
patients are shifting worldwide (global burden, younger patients,
more women, more insulin resistance/diabetes, more
hypertriglyceridaemia, and less low-density lipoprotein excess).
† Statin treatment and other preventive measures have begun to
modify atherosclerotic disease.
† ST segment elevation myocardial infarction wanes as non-ST
segment elevation myocardial infarction waxes.
† Plaque rupture declines as a cause of acute coronary syndromes
while superficial erosion appears on the rise.
† Plaques underlying cerebrovascular events reveal more stable
fibrous characteristics compared with that 10 years ago.
Figure 1 Contrasts between superficial erosion and fibrous cap rupture as causes of arterial thrombosis. Q6LDL, low-density lipoprotein.
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